Literature DB >> 22823084

The current role of model-based drug development.

Satyendra Suryawanshi1, Liping Zhang, Marc Pfister, Bernd Meibohm.   

Abstract

IMPORTANCE OF THE FIELD: Current drug discovery and development programs are under growing scrutiny for low productivity and escalating costs. Model-based drug development (MBDD) has been recognized as a promising tool to address some of the related challenges. AREAS COVERED IN THIS REVIEW: This review introduces the concept of MBDD and the associated quantitative pharmacology-based iterative 'learn and confirm' paradigm in the drug discovery and development process to provide concise information for rational decision making. It summarizes the evolving role of MBDD in drug development programs and outlines the full armamentarium of modeling and simulation approaches utilized to facilitate its application. WHAT THE READER WILL GAIN: Different aspects and applications of MBDD are introduced to the reader and illustrated in prime examples. The reader is provided with an understanding of potential applications of MBDD in drug development as well as the associated limitations and challenges in its implementation. TAKE HOME MESSAGE: MBDD is a tool that is increasingly used throughout the drug discovery and development continuum to support fast and rationale decision making and has thereby the potential to accelerate and increase the cost-effectiveness of the drug development process.

Year:  2010        PMID: 22823084     DOI: 10.1517/17460441003713470

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  7 in total

1.  Model based design and analysis of phase II HIV-1 trials.

Authors:  Dinko Rekić; Daniel Röshammar; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-11       Impact factor: 2.745

Review 2.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Authors:  Pavan K Vaddady; Richard E Lee; Bernd Meibohm
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

Review 3.  Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Authors:  Ashit Trivedi; Richard E Lee; Bernd Meibohm
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

Review 4.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

Review 5.  Recent developments in using mechanistic cardiac modelling for drug safety evaluation.

Authors:  Mark R Davies; Ken Wang; Gary R Mirams; Antonello Caruso; Denis Noble; Antje Walz; Thierry Lavé; Franz Schuler; Thomas Singer; Liudmila Polonchuk
Journal:  Drug Discov Today       Date:  2016-02-15       Impact factor: 7.851

Review 6.  Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges.

Authors:  Huixi Zou; Parikshit Banerjee; Sharon Shui Yee Leung; Xiaoyu Yan
Journal:  Front Pharmacol       Date:  2020-07-03       Impact factor: 5.810

Review 7.  Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity.

Authors:  C Anthony Hunt; Ryan C Kennedy; Sean H J Kim; Glen E P Ropella
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2013-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.